- Home
- VRTX vs COP Comparison
VRTX vs COP Comparison
Compare VRTX & COP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRTX
- COP
- Stock Information
- Founded
- VRTX 1989
- COP 1917
- Country
- VRTX United States
- COP United States
- Employees
- VRTX N/A
- COP N/A
- Industry
- VRTX EDP Services
- COP Integrated oil Companies
- Sector
- VRTX Technology
- COP Energy
- Exchange
- VRTX Nasdaq
- COP Nasdaq
- Market Cap
- VRTX 104.8B
- COP 123.0B
- IPO Year
- VRTX 1991
- COP N/A
- Fundamental
- Price
- VRTX $422.00
- COP $105.84
- Analyst Decision
- VRTX Buy
- COP Buy
- Analyst Count
- VRTX 30
- COP 17
- Target Price
- VRTX $503.92
- COP $136.19
- AVG Volume (30 Days)
- VRTX 2.1M
- COP 7.2M
- Earning Date
- VRTX 02-03-2025
- COP 02-06-2025
- Dividend Yield
- VRTX N/A
- COP 2.95%
- EPS Growth
- VRTX N/A
- COP N/A
- EPS
- VRTX N/A
- COP 8.44
- Revenue
- VRTX $10,625,800,000.00
- COP $56,924,000,000.00
- Revenue This Year
- VRTX $12.56
- COP N/A
- Revenue Next Year
- VRTX $8.34
- COP $11.33
- P/E Ratio
- VRTX N/A
- COP $12.54
- Revenue Growth
- VRTX 10.06
- COP N/A
- 52 Week Low
- VRTX $377.85
- COP $94.23
- 52 Week High
- VRTX $519.88
- COP $135.18
- Technical
- Relative Strength Index (RSI)
- VRTX 48.34
- COP 65.50
- Support Level
- VRTX $397.25
- COP $99.64
- Resistance Level
- VRTX $425.49
- COP $106.17
- Average True Range (ATR)
- VRTX 8.24
- COP 1.89
- MACD
- VRTX 3.71
- COP 1.09
- Stochastic Oscillator
- VRTX 79.84
- COP 96.71
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
About COP ConocoPhillips
ConocoPhillips is a US-based independent exploration and production firm. In 2023, it produced 1.2 million barrels per day of oil and natural gas liquids and 3.1 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2023 were 6.8 billion barrels of oil equivalent.